BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Given Average Recommendation of "Moderate Buy" by Brokerages

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) has earned a consensus rating of "Moderate Buy" from the nine ratings firms that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $16.56.

Several analysts recently issued reports on BCRX shares. JPMorgan Chase & Co. lifted their price target on shares of BioCryst Pharmaceuticals from $10.00 to $13.00 and gave the company an "overweight" rating in a research report on Tuesday, May 6th. HC Wainwright reaffirmed a "buy" rating and set a $30.00 price objective on shares of BioCryst Pharmaceuticals in a report on Tuesday, May 6th. Wall Street Zen raised shares of BioCryst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Thursday, May 22nd. Needham & Company LLC lifted their price objective on shares of BioCryst Pharmaceuticals from $15.00 to $17.00 and gave the stock a "buy" rating in a report on Tuesday, May 6th. Finally, Barclays lifted their price objective on shares of BioCryst Pharmaceuticals from $8.00 to $11.00 and gave the stock an "equal weight" rating in a report on Wednesday, May 7th.

BioCryst Pharmaceuticals Trading Up 1.4%

NASDAQ BCRX opened at $10.10 on Friday. The company has a fifty day simple moving average of $9.71 and a 200 day simple moving average of $8.49. BioCryst Pharmaceuticals has a 12-month low of $6.00 and a 12-month high of $11.31. The company has a market cap of $2.11 billion, a P/E ratio of -38.85, a PEG ratio of 2.28 and a beta of 1.11.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. raised its stake in shares of BioCryst Pharmaceuticals by 7.8% during the 4th quarter. Vanguard Group Inc. now owns 21,890,422 shares of the biotechnology company's stock worth $164,616,000 after purchasing an additional 1,583,826 shares during the period. Alkeon Capital Management LLC raised its stake in shares of BioCryst Pharmaceuticals by 1.7% during the 1st quarter. Alkeon Capital Management LLC now owns 7,214,021 shares of the biotechnology company's stock worth $54,105,000 after purchasing an additional 120,199 shares during the period. Millennium Management LLC raised its stake in shares of BioCryst Pharmaceuticals by 382.6% during the 1st quarter. Millennium Management LLC now owns 3,812,874 shares of the biotechnology company's stock worth $28,597,000 after purchasing an additional 3,022,769 shares during the period. Caligan Partners LP raised its stake in shares of BioCryst Pharmaceuticals by 16.0% during the 4th quarter. Caligan Partners LP now owns 2,995,932 shares of the biotechnology company's stock worth $22,529,000 after purchasing an additional 412,347 shares during the period. Finally, Two Sigma Advisers LP raised its stake in shares of BioCryst Pharmaceuticals by 14.6% during the 4th quarter. Two Sigma Advisers LP now owns 2,499,812 shares of the biotechnology company's stock worth $18,799,000 after purchasing an additional 318,800 shares during the period. 85.88% of the stock is currently owned by institutional investors.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.